



82-34639

**AGENIX LIMITED**

11 Durbell Street P.O. Box 391

Acacia Ridge QLD 4110

Australia

Tel : +61 (0)7 3370 6396

Fax : +61 (0)7 3370 6370

Website : www.agenix.com


~~SEC#82-5258~~



SUPPL

21 October 2005

US Securities and Exchange Commission  
Attention: Filing Desk  
450 Fifth Street NW  
WASHINGTON DC 20549  
USA



Dear Sir

**Re: Submission Under Rule 12g3-2(b) - Agenix Limited**

We refer to the attached announcement that was made to the Australian Stock Exchange on 20 October 2005.

We are providing a copy of the announcement by virtue of our requirements under Rule 12g3-2(b).


Yours sincerely

Neil Leggett  
Company Secretary

PROCESSED

NOV 01 2005

THOMSON  
FINANCIAL



20 October 2005

## AGENIX COMPLETES \$10.3 MILLION CAPITAL RAISING

Agenix announces the successful completion of a \$10.3 million capital raising to fund the manufacturing scale up and supply of its ThromboView<sup>®</sup> product required for phase III clinical trials and the first year's sales after obtaining registration.

Following the close on Monday 17 October 2005 of the non-renounceable 1:4 entitlements offer at \$0.25, plus over-subscription facility, Agenix notifies the ASX, pursuant to Listing Rule 7, that:

- Shareholders exercising their rights applied for 20,739,412 shares at \$0.25 each to raise \$5,184,853.00.
- Under an over-subscription facility for a maximum aggregate of 2,000,000 shares, shareholders applied for 6,833,444 shares amounting to \$1,708,361.00.
- The Underwriter, Intersuisse Limited, has placed the shortfall under the issue of 18,652,479 shares at \$0.25 amounting to \$4,663,119.75, to institutional, sophisticated and other investors pursuant to s708 of Corporations Act.
- The Underwriter has secured participation from a major international institutional investor for 8,000,000 shares.

The new shares will be allotted on 25 October 2005.

**ENDS**

**For more information contact:**

Mr Donald Home  
Managing Director  
Agenix Limited  
Ph: + 61 7 3370 6300

Neil Leggett  
Finance Director  
Agenix Limited  
Ph: +61 7 3370 6300

Jonathan Buckley  
Director  
Intersuisse Corporate P/L  
03 9618-8244

**Agenix Limited [ASX: AGX; OTC (NASDAQ): AGXLY]** is a global health and biotechnology company based in Brisbane, Australia. The Company runs a suite of established businesses in human and animal health diagnostics, and is focused on growing its world-leading molecular diagnostic imaging R&D program. Agenix's lead candidate is its high-technology ThromboView<sup>®</sup> blood clot-imaging project, which is currently undergoing Phase II human trials in the United States and Canada. ThromboView<sup>®</sup> uses radiolabelled antibodies to locate blood clots in the body, and could revolutionise the US \$3 billion global clot diagnostic imaging market. ThromboView<sup>®</sup> is being developed with the assistance of the Federal Government through its START scheme. Agenix employs 90 staff and sells its products to more than 50 countries. ThromboView<sup>®</sup> is a registered trademark of AGEN Biomedical Ltd, a wholly owned subsidiary of Agenix Limited.